PH12017501549B1 - Peptides for inhibiting angiogenesis - Google Patents

Peptides for inhibiting angiogenesis

Info

Publication number
PH12017501549B1
PH12017501549B1 PH12017501549A PH12017501549A PH12017501549B1 PH 12017501549 B1 PH12017501549 B1 PH 12017501549B1 PH 12017501549 A PH12017501549 A PH 12017501549A PH 12017501549 A PH12017501549 A PH 12017501549A PH 12017501549 B1 PH12017501549 B1 PH 12017501549B1
Authority
PH
Philippines
Prior art keywords
peptides
inhibiting angiogenesis
methods
relates
present
Prior art date
Application number
PH12017501549A
Other languages
English (en)
Other versions
PH12017501549A1 (en
Inventor
Yulia A Komarova
Mark Rosenblatt
Asrar B Malik
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of PH12017501549A1 publication Critical patent/PH12017501549A1/en
Publication of PH12017501549B1 publication Critical patent/PH12017501549B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00844—Feedback systems
    • A61F2009/00851—Optical coherence topography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00863—Retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865—Sclera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872—Cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PH12017501549A 2015-03-02 2017-08-29 Peptides for inhibiting angiogenesis PH12017501549B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562126968P 2015-03-02 2015-03-02
PCT/US2016/020443 WO2016141053A1 (en) 2015-03-02 2016-03-02 Peptides for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
PH12017501549A1 PH12017501549A1 (en) 2018-02-05
PH12017501549B1 true PH12017501549B1 (en) 2021-12-15

Family

ID=55543089

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501549A PH12017501549B1 (en) 2015-03-02 2017-08-29 Peptides for inhibiting angiogenesis

Country Status (18)

Country Link
US (2) US9675660B2 (enExample)
EP (1) EP3265110B1 (enExample)
JP (1) JP6896641B2 (enExample)
KR (1) KR20170122762A (enExample)
CN (1) CN107427549B (enExample)
AU (1) AU2016226264B2 (enExample)
BR (1) BR112017018665A2 (enExample)
CA (1) CA2977389A1 (enExample)
DK (1) DK3265110T3 (enExample)
ES (1) ES2820710T3 (enExample)
IL (1) IL253966B (enExample)
MX (1) MX2017011170A (enExample)
PH (1) PH12017501549B1 (enExample)
PL (1) PL3265110T3 (enExample)
RU (1) RU2708375C2 (enExample)
SG (1) SG11201706799YA (enExample)
WO (1) WO2016141053A1 (enExample)
ZA (1) ZA201705934B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020053773A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
KR20210062649A (ko) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. 펩티드 및 이의 의학적 용도
CN113755634A (zh) * 2021-10-12 2021-12-07 河南省农业科学院烟草研究所 一种鸢尾丝囊霉菌分子检测的特异引物及其检测方法
CN115737677B (zh) * 2022-07-25 2024-09-06 天津医科大学总医院 一种多肽修饰的金纳米颗粒在制备抑制糖尿病视网膜病变药物中的用途
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CN101014358A (zh) * 2003-10-29 2007-08-08 约翰·霍普金斯大学 色素上皮所衍生因子的生物活性及使用方法
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
EP1786451A4 (en) * 2004-08-06 2009-07-22 Sopherion Therapeutics Inc ANTIANGIOGENIC PEPTIDES AND METHOD FOR THEIR USE
JP5548616B2 (ja) * 2007-08-08 2014-07-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
BRPI0903901A2 (pt) * 2008-04-16 2017-05-23 Univ Of Utah Res Foudation composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
EP2439514A1 (en) 2010-10-01 2012-04-11 Aqsens Oy Method, apparatus, and system for examining optically a sample carried in a plurality of wells
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用

Also Published As

Publication number Publication date
MX2017011170A (es) 2018-04-24
SG11201706799YA (en) 2017-09-28
AU2016226264A1 (en) 2017-08-31
US9675660B2 (en) 2017-06-13
RU2017133101A (ru) 2019-04-02
RU2708375C2 (ru) 2019-12-06
PL3265110T3 (pl) 2020-12-28
IL253966B (en) 2019-12-31
ZA201705934B (en) 2018-12-19
JP6896641B2 (ja) 2021-06-30
HK1247573A1 (zh) 2018-09-28
CN107427549A (zh) 2017-12-01
IL253966A0 (en) 2017-10-31
ES2820710T3 (es) 2021-04-22
EP3265110B1 (en) 2020-07-15
EP3265110A1 (en) 2018-01-10
CN107427549B (zh) 2022-01-11
AU2016226264B2 (en) 2021-04-01
US20160256518A1 (en) 2016-09-08
PH12017501549A1 (en) 2018-02-05
BR112017018665A2 (pt) 2018-04-24
JP2018508528A (ja) 2018-03-29
DK3265110T3 (da) 2020-10-19
KR20170122762A (ko) 2017-11-06
RU2017133101A3 (enExample) 2019-07-26
HK1248101A1 (zh) 2018-10-12
US10064911B2 (en) 2018-09-04
WO2016141053A1 (en) 2016-09-09
CA2977389A1 (en) 2016-09-09
US20170258868A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021002897A (es) Metodos de tratamiento y prevencion de la disfuncion endotelial utilizando metil bardoxolona o sus analogos.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MY202415A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2016016881A (es) Anticuerpos que se unen a axl.
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12017501549A1 (en) Peptides for inhibiting angiogenesis
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
PH12017501872A1 (en) Methods of treating diseases
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
IN2014MU00675A (enExample)
GB201504587D0 (en) Improvements in methods of treating tobacco.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
SI3233110T1 (sl) Ciklični acetilholinesterazni c-terminalni peptid pri zdrvaljenju ali preprečevanju raka ali metastaz
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis